TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis
14.1.2026 18:30:00 CET | Business Wire | Press Release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/
Fachklinik Schömberg
Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents and patients while maintaining close alignment between real estate ownership and operations.
The investment has been structured through the subscription of financial securities, including preferred shares, designed to deliver stable and predictable returns, with a minimum 6% yield and an expected unlevered IRR of approximately 12%.
This transaction represents a further step in TwentyTwo Real Estate’s strategy of investing in operationally intensive assets within the living and healthcare sectors, where strong real estate fundamentals, combined with operational expertise, underpin long-term, sustainable value creation. It follows the recent launch of the firm’s senior living investment platform, Premior Residences, seeded with an initial portfolio of c.1,900 units, and reflects TwentyTwo Real Estate’s continued expansion in Western Europe, as well as its focus on thematic investments driven by major demographic and societal trends.
Daniel Rigny, Founder and Chairman of TwentyTwo Real Estate, commented:
“This investment represents a major step in our expansion into healthcare and operational living real estate. Isemia’s portfolio comprises high-quality assets, characterized by their resilience and strong social utility. In partnership with emeis and Farallon Capital, we are establishing a leading real estate company addressing Europe’s structural demographic and healthcare needs while delivering robust fundamentals and sustainable value creation for long-term investors. We are proud to have completed this strategic transaction, which reflects our investment convictions, our ability to design innovative financial solutions and our capacity to mobilize our operational expertise.”
About TwentyTwo Real Estate
TwentyTwo Real Estate is an independent real estate investor and operator with €5.2 billion in assets under management in Europe. Founded in 2012 by Daniel Rigny, the group combines cutting-edge financial expertise and operational excellence to offer its institutional and private clients a range of high value-added investment solutions and real estate services across all asset classes. TwentyTwo Real Estate's mission is to create sustainable value for its investors, clients, and employees, while having a positive impact on society and the environment.
About Farallon
Farallon Capital is a global investment management firm with over $40 billion in assets under management on behalf of a wide range of institutions, including university endowments, charitable foundations, and pension funds. Founded in 1986 and based in San Francisco, Farallon is an experienced institutional investment management firm investing across a variety of asset classes and jurisdictions. It aims to generate attractive risk-adjusted returns for its investors through rigorous fundamental analysis, a bottom-up approach and a focus on capital preservation.
About emeis
With nearly 83,500 experts and professionals in healthcare, nursing and support for the most vulnerable, emeis is present in some 20 countries and covers five business lines: psychiatric clinics, medical and rehabilitation clinics, nursing homes, home care and services, and assisted living facilities. emeis welcomes nearly 280,000 residents, patients, and beneficiaries each year. emeis is committed to addressing one of the major challenges facing our societies: the increase in the number of people made vulnerable by accidents, old age, or mental illness. emeis, which is 50.3% owned by Caisse des Dépôts, CNP Assurances, MAIF and MACSF Epargne Retraite, is listed on Euronext Paris (ISIN: FR001400NLM4) and is a member of the SBF 120 and CAC Mid 60 indices.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260114262830/en/
Contacts
Press Contact
TwentyTwo Real Estate
https://twentytwo.com/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwentytwo.com%
2F&esheet=54396617&newsitemid=20260114262830&lan=en-US&anchor=https%3A%2F%2Ftwen
tytwo.com%2F&index=2&md5=1e7b78ddba62c63626ee4628697cbf80
Dina Sanches – Communication Manager
M + 33 (0) 6 63 04 22 78 │dsanches@twentytwo.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 10:08:00 CET | Press Release
Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network APIs, Communications APIs, and developer tools - enabling them to copy, or fork, collections into their own workspaces and build, test, and collaborate in real time with other developers and teams. This
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press Release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press Release
NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom